Value in Health - McMaster Experts

publication venue for

The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health: A Systematic Review of Canadian Studies 2023
ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY 2022
CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING 2022
DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS 2022
PRACTICAL CONSIDERATIONS FOR DEVELOPING PICO STATEMENTS FOR HUMANISTIC BURDEN REVIEWS: HOW TO GET IT RIGHT 2022
RESOURCE USE AND COSTS ASSOCIATED WITH COMPUTERIZED DECISION SUPPORT SYSTEM FOR MANAGING PATIENTS WITH ATRIAL FIBRILLATION 2022
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG GENERALIZED PUSTULAR PSORIASIS PATIENTS: A CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS 2022
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG PALMOPLANTAR PUSTOLOSIS PATIENTS: A 10-YEAR CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS 2022
Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics 2022
COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS 2022
IMPACT OF DEPRESSION RELAPSE ON PARTICIPANT QUALITY OF LIFE AND COSTS TO THE ENGLISH NHS: SECONDARY ANALYSIS FROM THE ANTLER STUDY ON ANTIDEPRESSANT DISCONTINUATION IN WELL PATIENTS IN PRIMARY CARE 2022
THE IMPACT OF KEY HEALTH STATE TRANSITIONS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A QUALITATIVE STUDY 2022
TIME TRADE-OFF UTILITY VALUES FOR HEALTH STATES CHARACTERIZING PROGRESSIVE MUSCULAR DEGENERATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) 2022
ECONOMIC COST OF IN CANADA: A MULTI-CENTRE, RETROSPECTIVE STUDY 2022
PLATFORM TRIALS: A PATH TO EFFICIENT DECISION MAKING AND FASTER DRUG APPROVALS FOR HEALTH TECHNOLOGY ASSESSMENT BODIES 2022
SYSTEMATIC REVIEW OF PROBABILISTIC SENSITIVITY ANALYSIS METHODS IN MICROSIMULATION OF CHRONIC DISEASES 2022
THE DRIVERS OF HEALTH STATE UTILITIES IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A STUDY USING THE HEALTH UTILITIES INDEX MARK 3 (HUI3) 2021
WHAT IS VALUE? A SYSTEMATIC REVIEW OF VALUE ASSESSMENT FRAMEWORKS 2021
IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT) 2020
COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK 2019
ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS 2019
UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW 2019
PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY 2019
PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING 2019
PNS88 IMPACT OF PATIENT-TARGETED FINANCIAL INCENTIVES ON HEALTHCARE COSTS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS 2019
ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE 2018
PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL 2018
Budget Impact of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) in the UK 2018
Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK) 2018
Cost-Minimization Analysis of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (Copd) in the UK 2018
Economic Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the Torch Study 2018
Evidence Driven Cancer Drug Approvals In Phase II Versus Phase III Clinical Trials Within A Single-Payer Public Healthcare System 2018
First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem 2018
How Values Inform the Health Policy Decision-Making Processes About Health-System Financing in Latin America? A Critical Interpretive Synthesis 2018
Respiratory Illness (RI) and Respiratory Syncytial Virus (RSV)-Related Hospitalization (RSVH) in Infants with Congenital Diaphragmatic Hernia (CDH) in the Caress Registry (2005-2017) 2018
United States Valuation of EQ-5D-5L Health States: An Initial Model Using a Standardized Protocol 2018
Development of A New Patient-Reported Outcome Instrument To Evaluate Treatments For Stretchmarks: The Body-Q Stretchmark Scale 2017
Economic Evaluation of Single Inhaler Triple Therapy For Patients With Chronic Obstructive Pulmonary Disease (COPD) Using The Galaxy Model 2017
Estimating the Comparative Accuracy of Diagnostic Tests: AN Example using Typhoid Fever 2017
Health and Economic Benefits of Using Single Versus Multiple Inhalers in Patients with Asthma: A Systematic Literature Review 2017
Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions 2017
Reliability, Validity and Responsiveness of A New Measure of Neck Disability (ND10) 2017
Single Versus Multiple Inhalers in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review 2017
Translation And Cultural Adaptation Of The Body-Q Chest Module Into Finnish For Use In Gynecomastia, Weight Loss And FTM Chest Surgery 2017
A META-EPIDEMIOLOGICAL SURVEY OF THE REPORTING OF EFFECT MODIFICATION IN NETWORK META-ANALYSES 2017
CONSIDERATIONS IN THE ECONOMIC EVALUATION OF NURSE PRACTITIONERS AND CLINICAL NURSE SPECIALISTS ROLES 2017
COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK 2017
COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN PSORIATIC ARTHRITIS: A CANADIAN PERSPECTIVE 2017
RESPIRATORY ILLNESS AND RESPIRATORY SYNCYTIAL VIRUS (RSV)-RELATED HOSPITALIZATION (RSVH) IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES (CAA) IN THE CARESS REGISTRY (2005-2016) 2017
ROBOTIC-ASSISTED THORACOSCOPIC PULMONARY RESECTION VERSUS VIDEO-ASSISTED THORACOSCOPIC PULMONARY RESECTION FOR EARLY STAGE NON-SMALL CELL LUNG CANCER: A HEALTHCARE UTILIZATION ANALYSIS 2017
Factors Influencing Door-To-Doctor Time In An Emergency Department: Discrete Event Simulation Model 2016
Linguistic Validation of the Finnish Version of the Body-Q Pro Instrument 2016
NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF LINAGLIPTIN, EMPAGLIFLOZIN AND THE FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) 2016
Comparison Of First- And Second-Season Palivizumab Prophylaxis In Patients With Congenital Airway Anomalies (Caa) In The Caress Database (2005-2015) 2016
Dalteparin Versus Vitamin K Antagonists for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer and Renal Impairment: Pharmacoeconomic Analysis of a Prospective Randomized Trial 2016
Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review 2016
NURSE-LED CARE FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW 2016
Trends In Oral Glucocorticoid Utilization Among Older Adults With Respiratory Disease 2016
Propensity Score Matching Does not Always Remove Confounding within an Economic Evaluation Based on a Non-Randomized Study 2015
The Cost-Effectiveness of Referring Patients With Irritable Bowel Syndrome To A Gastroenterologist In The Uk 2015
A review of health-related quality of life (hrql) claims in labels of asthma products â€“ can we consider the asthma quality of life questionnaire (aqlq) as a potentially acceptable measure for qualification? 2015
Assure-Csu Canadian Results: Assessing Health Utility In Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d 2015
Comparing First- and Second-Season Palivizumab Prophylaxis In Patients with Hemodynamically Significant Congenital Heart Disease in the Caress Database (2005-2014) 2015
Respiratory Related Hospitalizations In Premature Infants Prophylaxed With Palivizumab In the Canadian Registry of Palivizumab (Caress) 2015
Serious Adverse Events In Canadian Children Receiving Palivizumab for the Prevention of Respiratory Syncytial Virus Infection 2015
The Economic Value of Tofacitinib 5 Mg Bid In The Treatment of Moderate To Severe Rheumatoid Arthritis: A Canadian Analysis 2015
The Processes For A Common Quality Assurance Approach To Multi-Centre Clinical Trials â€“ The Mars Excite Experience 2015
Usability Testing Of The Web-Based Versions Of The Standardised Asthma Quality Of Life Questionnaire For 12 Years And Older (Aqlq(S)+12) And The Asthma Control Questionnaire (Acq-6) 2015
Acute And Chronic Impact Of Cardiovascular Events On Health State Utilities 2014
Concomitant Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) And Proton Pump Inhibitors (Ppis) in Newly Diagnosed Patients With Osteoarthritis (Oa), Rheumatoid Arthritis (Ra) or Ankylosing Spondylitis (As) 2014
A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment 2014
An Examination Of Disparity In Access To Mental Health Services Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario 2014
Budget Impact Analysis Of Dolutegravir In The Treatment Of Human Immunodeficiency Virus (Hiv) In Ontario, Canada 2014
Burden of illness of diabetic foot ulcers in Canada 2014
Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: A bayesian indirect treatment comparison meta-analysis 2014
Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting 2014
Cost-Utility Analysis of Practice Deviations From Guidelines in HER2-Targeted Testing and Treatment for Breast Cancer 2014
Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis 2014
Cost–Effectiveness Analysis Parallel to a Randomized Controlled Trial Comparing Vertical Scar Reduction (VSR) and Inverted T-Shaped Reduction (ITR) Mammoplasty 2014
EQ-5D health utilities are estimated subject to considerable uncertainty 2014
Evaluation Of A Chronic Disease Management System For The Treatment And Management Of Diabetes In Primary Health Care Practices In Ontario 2014
Factors associated with large increases in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from the bioadvance survey 2014
Follow-Up Of Psychoactive Drug Use In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada) 2014
Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre 2014
Health State Utilities Associated With Attributes Of Treatments For Hepatitis C 2014
Increased In Acute Health Care Use Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario: A Longitudinal Study 2014
Mammographic Density in Association with Smoking Status and Smoking Histories in a Sample of Postmenopausal Women: Results From a Cross-Sectional Study 2014
Prevalence And Incidence Of Interstitial Pulmonary Diseases With Fibrosis 2014
Psychiatric Health Care Utilisation And Related Costs In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada) 2014
Real World Drug Utilization Of Hiv Therapies In Canada 2014
Respiratory Syncytial Virus Prophylaxis In Down Syndrome: A Prospective Cohort Study 2014
Screening For Type 2 Diabetes: A Methodological Review And Cost Analysis 2014
Some statistical considerations in estimating a disease progression model for chronic obstructive pulmonary disease (COPD) 2014
Survival crossover adjustment and cost effectiveness analysis: An empirical and methodological review with application 2014
The Canadian Eq-5d Valuation Study: Estimating Time Trade-Off Values For The Eq-5d-5l 2014
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario 2014
Time trade-off utility assessment with a 10-year time horizon: when should alternative approaches be considered? 2014
Use Of Economic Evidence To Inform Drug Reimbursement Decision Making: The Case For Ontario 2014
Adherence Interventions to Improve Adherence to Antiretroviral Therapy in Low Income Settings: An Individual Patient Data Network Meta-Analysis 2013
Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies 2013
Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada) 2013
Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages 2013
Easing Decision-Making by Expanding Methods of Multiple Treatment Comparison Meta-Analysis – Incorporating Non-Comparative Studies Via Informative Priors 2013
Factors Associated with Compliance with Palivizumab Prophylaxis in the Canadian RSV Evaluation Study for Synagis (CARESS) Registry (2005-2012) 2013
Health Utilities Index (Hui®): Population Reference Statistics 2013
Impact of Major Clinical Events on Utilities in the Context of Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) Treated with Dialysis 2013
Measuring Pros That Matter to Bariatric and Body Contouring Surgery: The Body-Q 2013
Modeling a Switch from Trivalent to Quadrivalent Influenza Vaccine in Canada and the United Kingdom 2013
Multinational Consistency of a Discrete Choice Model in Quantifying Health States for the Extended 5-Level EQ-5D 2013
Psychoactive Drug Use, Polypharmacy and Co-Morbidities in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec 2013
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES IN THE CANADIAN REGISTRY OF SYNAGIS (R) (CARESS) FOLLOWING PROPHYLAXIS (2005-2012) 2013
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS) 2013
A cost-minimization analysis of a new fixed-dose combination of dutasteride and tamsulosin compared to concomitant administration of both monotherapies for the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada 2013
Are canadians different from americans in stated preferences for health? valuing EQ-5D-5L health states using discrete choice experiments 2013
CAN INDIVIDUAL HEALTH TECHNOLOGIES IMPROVE OVERALL CHRONIC DISEASE MANAGEMENT? 2013
COMPARING EQ-5D VALUATION STUDIES: A SYSTEMATIC REVIEW AND METHODOLOGICAL REPORTING CHECKLIST 2013
Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario 2013
Cost-effectiveness of ticagrelor versus generic clopidogrel in patients with acute coronary syndromes in Canada 2013
Costs and health care resource utilization associated with asthma in canada: A systematic review 2013
DEVELOPMENT OF THE 6-10 YEAR INTERVIEWER-ADMINISTERED VERSION OF THE ASTHMA CONTROL QUESTIONNAIRE (ACQ-IA) IN SPANISH FOR GUATEMALA AND PERU 2013
Excite – A New Collaborative Model Of Pre-Market Evaluation Of Health Technologies 2013
HEALTH UTILITIES INDEX (R) : EXTENDING THE AGE RANGE TO PRE-SCHOOLERS 2013
Harmonization Of Health Technology Assessement And Regulatory Processes And Evidentiary Requirements For Drugs And Devices: Opportunities And Challenges 2013
How can we use discrete event simulation to improve access to health care: an assessment of increasing access to care for children with medically refractory epilepsy 2013
Impact of multiple treatment comparison meta-analysis on value of information evaluations: a case study of pharmacotherapies for chronic obstructive pulmonary diseases 2013
Modelling drug class effects in bayesian multiple treatment comparison meta-analysis: Applications in early and advanced parkinson's disease 2013
Psychometric Development Of A New Pro Instrument: The Face-Q Scales For Facelift Patients 2013
Reliability and validity of current perception threshold test in mechanical neck disorder 2013
Responsiveness Of The Face-Q: A New Pro For Facial Aesthetic Paitents 2013
Rsv Hospitalization In Infants With Neuromuscular Disease In The Canadian Registry Of Synagis® (Caress) Following Prophylaxis (2005-2012) 2013
Systematic review of cost-effectiveness analyses of dabigatran versus warfarin for atrial fibrillation across different health care systems 2013
The effects of excluding treatments from network meta-analysis 2013
Underestimation of uncertainties in health utilities dervied from mapping algorithms involving health-related quality of life measures: statistical explanations and potential remedies 2013
Valuing EQ-5D-5L: Can latent utilities derived from a discrete choice model be transformed to health utilities derived from time trade-off tasks? 2013
Why are the findings of cost-effectiveness analyses of biologic treatment for rheumatoid arthritis so different? 2013
Why are the findings of indirect comparisons of boceprevir and telaprevir for hepatitis C infection different? A methodological review 2013
CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA 2012
CL3 Calibrating Bayesian Multiple Treatment Comparison Meta-Analysis With Multiple Cost-Effectiveness Acceptability Curves 2012
PCN110 Differences in Health-Related Quality of Life Between Children Treated for Acute Lymphoblastic Leukemia (ALL) on Dana Farber Cancer Institute (DFCI) Protocols 2012
PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada 2012
PDB77 Characteristics of Patients With Diabetes in Southwestern Ontario, Canada 2012
PHP174 Physical Activity Matters: The Associations Between Body Mass Index, Physical Activity and Health-Realted Quality-of-Life Trajectories Over 10 Years 2012
PHP202 Bridging the Gap Between Institutional Levels Using Systems Analysis 2012
PMS6 Anti-Tumour Necrosis Factor (TNF) Drugs for the Treatment of Psoriatic Arthritis (PsA) 2012
PMS60 The Time Horizon Matters: Exploratory Results Varying the Time Horizon in Time Trade-Off and Standard Gamble Utility Elicitation 2012
PRM148 Sample Size and Power Considerations in Network Meta-Analysis 2012
PRM6 Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis 2012
PRS39 Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension 2012
PSU11 Medical Costs Comparison Between Internal Fixation and Arthoplasty in Patients With Hip Femoral Neck Fractures 2012
EMPIRICAL EXAMINATION OF STARTING POINT BIAS WITH THE BIDDING GAME IN A WILLINGNESS-TO-PAY ANALYSIS 2012
MO4 Economic Evaluation of Treatment Strategies for Late-Presentation Acute Ischemic Stroke 2012
PCV5 Intra-Arterial Thrombolysis Versus Standard Treatment or Intravenous Thrombolysis in Adults with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis 2012
PIH12 Budget Impact Analysis of Adding a New Fixed-Dose Combination Therapy of Dutasteride and Tamsulosin to the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada 2012
PIH16 Cost-Effectiveness of a New Fixed-Dose Combination of Dutasteride and Tamsulosin for the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada 2012
PIH39 Eliciting Preferences to the EQ-5D-5L Health States: Discrete Choice Experiment or Multiprofile Case of Best-Worst Scaling 2012
PIH56 Measuring Quality of Life in Facial Aesthetic Patients: Field-Testing of a New Modular System (the FACE-Q) 2012
PIN30 Economic Evaluation of a Cluster Randomized Controlled Trial of an Influenza Immunization Program Directed at Healthy Children 2012
PMD25 Comparison of Statistical Methods Used to Model Health Care Costs by Dialysis Modality in the Treatment of Kidney Failure 2012
PMD3 Does Current Perception Threshold Test Can Differentiate Categories of Mechanical Neck Disorder? 2012
PMD8 Efficacy of Systemic Hyperbaric Oxygen Therapy for Non-Healing Diabetic Ulcers of the Lower Limb: Systematic Review and Meta-Analysis 2012
PMS85 Why the Findings of Published Rheumatoid Arthritis Multiple Treatment Comparisons are So Different - An Overview of Recurrent Methodological Shortcomings 2012
PMS90 the Influence of ‘Weak Links' on Comparative Treatment Effects in Multiple Treatment Comparison Meta-Analysis: A Simulation Study 2012
PRM28 Physicians as Pseudo-Agents in a Hospital Emergency Department Discrete Event Simulation 2012
PRS52 The Stability of Additive Treatment Effects in Multiple Treatment Comparison Meta-Analysis: a Simulation Study 2012
PSY65 Meta-Analysis of Health-Related Quality of Life Outcomes – Methods for Enhancing Interpretability of Findings 2012
A COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN PREMATURE INFANTS 2011
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2005-2010) 2011
PCN112 Cost-Utility of Treatment for Acute Lymphoblastic Leukemia (ALL) in Childhood 2011
PCN127 Health State Utility Assessment for Breast Cancer 2011
PCN175 Reimbursement of Anticancer Drugs in Canada: What Can We Learn from the Nice New Appraisal Process for Life-Extending End-of-Life Treatments? 2011
PCV110 Health-Related Quality of Life After Venous Thromboembolism 2011
PCV50 Hospital Costs Associated with Atrial Fibrillation in Canada 2011
PHP158 Determining the Monetary Value of a Quality-Adjusted Life Year (QALY): Systematic Review of the Evidence 2011
PIH27 Potential Health and Economic Impact of Adding Rotarixtm to Routine Infant Vaccination Programs in Canada 2011
PMD34 Cost Effectivness of Ambulatory Cardiac Monitor versus Holter 2011
PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies 2011
PMH26 Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model 2011
PMS22 The Burden of Illness of Osteoporosis in Canada 2011
PSY41 Health Status and Health-Related Quality of Life Reported by Females with Bleeding Disorders from the Canadian National Haemophilia Registry 2011
RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN SPECIAL POPULATIONS 2011
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS) 2011
PDB76 DESIGNING A SERVICE FRAMEWORK FOR ELECTRONIC PERSONAL HEALTH RECORDS: A PATIENT-CENTRED APPROACH 2011
PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN COST EFFECTIVENESS ANALYSIS 2011
PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO 2011
PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS 2011
PRM29 METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS: A SYSTEMATIC REVIEW AND ANALYSIS 2011
PSY23 ECONOMIC EVALUATION OF ERYTHROPOIESIS STIMULATING AGENTS IN CRITICALLY ILL TRAUMA PATIENTS 2011
PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA) 2011
PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2011
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2006-2009) 2010
PDB35 COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI:A CANADIAN PERSPECTIVE 2010
PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION 2010
PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA 2010
PRS42 EFFECTS OF ASTHMA MANAGEMENT, SOCIOECONOMIC STATUS AND MEDICATION INSURANCE CHARACTERISTICS ON EXACERBATION FREQUENCY IN CHILDREN WITH ASTHMA 2010
RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS 2010
HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO 2010
PCN143 COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW 2010
PCN31 COST COMPARISON OF INPATIENT AND OUTPATIENT HOSPITALBASED SERVICES BETWEEN TWO STRATEGIES FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A PUBLICLY FUNDED HEALTH CARE SYSTEM 2010
PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE 2010
PIN14 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-CONSEQUENCE ANALYSIS OF A 7-, 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CANADA 2010
PMS74 USE OF A DISEASE-SPECIFIC INSTRUMENT IN ECONOMIC EVALUATIONS: MAPPING WOMAC ONTO THE EQ-5D UTILITY INDEX 2010
PR4 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING 2010
PRS7 TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE 2010
PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY 2010
UT3 RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD 2010
UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO 2010
DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES 2009
MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION 2009
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R 2009
PCN130 HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL 2009
PCN31 A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY 2009
PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY 2009
PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS 2009
PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE 2009
PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW 2009
PIN33 POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH 2009
PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA 2009
PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION 2009
PMH18 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE 2009
PMH2 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE 2009
PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC 2009
PND46 A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP 2009
PND47 ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS 2009
PND48 SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION 2009
PSY18 THE BURDEN OF OBESITY IN ONTARIO 2009
PSY30 COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA 2009
PSY38 ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY 2009
PSY42 BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY: AN EXAMINATION OF QUALITY OF LIFE 2009
HT2 HEALTH TECHNOLOGY ASSESSMENT – A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO 2009
PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA 2009
PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS 2009
PIH11 ECONOMIC EVALUATION ALONGSIDE THE CAFFEINE FOR APNEA OF PREMATURITY (CAP) TRIAL: SHORT TERM OUTCOMES 2009
PIH56 CARESS: THE CANADIAN REGISTRY OF SYNAGIS, SUMMARY OF 2006–2008 RSV SEASONS 2009
PIH9 A SIMULATION MODELING OF THE EFFECT OF DOSING SCHEDULE ON THE BENEFIT AND COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN CANADA 2009
PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH: A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS 2009
PMS43 IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS? 2009
PMS45 EXTENSION FROM INPATIENTS TO OUTPATIENTS: PERFORMANCE OF THE OXFORD KNEE SCORE IN MEASURING HEALTH OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS 2009
PND26 UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA 2009
PSS2 DISTRIBUTION OF PATHOGENS ASSOCIATED WITH ACUTE OTITIS MEDIA: A SYSTEMATIC REVIEW OF THE LITERATURE 2009
PSS9 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COSTCONSEQUENCE ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7) 2009
PSY9 USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO 2009
QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA 2009
VA2 COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA 2009
CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS 2008
PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION 2008
PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES 2008
PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES? 2008
PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES? 2008
CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES 2008
DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA 2008
OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE 2008
PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL: AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3) 2008
PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM) 2008
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN 2008
PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA 2008
PCV67 RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE 2008
PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE 2008
PHP25 TOWARD HIGH PERFORMANCE ‘PHARMACARE’ SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES 2008
PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST? 2008
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA 2008
PIH22 CARESS: THE CANADIAN REGISTRY OF SYNAGIS(®) 2008
PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN 2008
PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS 2008
PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE: POPULATION-BASED NATURAL EXPERIMENT 2008
PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT 2008
PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS 2008
PR1 VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURINGTREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD 2008
PAR32 INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT 2007
PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT 2007
PCN45 A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: RESOURCE INTENSITY WEIGHTS (RIWS) AND THE HEALTH UTILITIES INDEX (HUI) 2007
PND27 DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8 2007
PST3 THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED STROKE CARE IN CANADA 2007
PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE 2006
PCN70 RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS 2006
PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS 2006
PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS 2006
PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA 2006
PRS13 USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS: EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA 2006
PRS16 MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY 2006
CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA 2006
PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS 2006
PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA 2006
PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT 2006
PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS 2006
PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL 2006
PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY 2006
PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA 2006
PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER? 2006
PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY 2006
PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA) 2006
PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE 2005
PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS 2005
PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE 2005
PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY 2005
PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES 2005
PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY 2005
PST10 THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE 2005
PCN23 RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD:AGREEMENT BETWEEN PATIENTS, PARENTS, AND PHYSICIANS 2005
PCN25 RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER 2005
PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY 2004
PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION 2004
PIN26 VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS 2004
PCN22 THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF ENGLISH VERSION IN SINGAPORE 2004
PCN26 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN 2004
PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY 2004
SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES 2004
CE1 COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA 2003
Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH) 2003
PCHI5: AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD THEIR PARENTS AND THEIR DOCTORS IN URUGUAY 2003
PGS6: THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD): COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY 2003
PIN6: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE 2003
PIN9: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES 2003
Is there any relationship between compliance and HRQoL in patients with heart failure? 2002
PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE? 2002
PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE 2002
The impact of an educational intervention on multiple health realted quality of life measures in patients with heart failure (HF) 2002
Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach. 26:1721-1729. 2023
Whose Time Trade-Off Should Be Used? Anchoring Discrete Choice Experiment Latent Utilities in Health State Valuation. 26:1405-1412. 2023
Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma. 26:1249-1257. 2023
P31 The Association between Patient- and Caregiver-Reported Utility Values in Duchenne Muscular Dystrophy (DMD). 26:S7-S7. 2023
PCR230 Estimating Utility Values Using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): A New Preference-Based Measure for Duchenne Muscular Dystrophy. 26:S355-S355. 2023
Modeling Tiered Pricing Frameworks: A Simulation Approach. 26:351-358. 2023
Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties. 26:251-260. 2023
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting. 25:S39-S39. 2022
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy. 25:S52-S52. 2022
EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants. 25:S137-S138. 2022
EE528 Resource Use and Costs Associated With Computerized Decision Support System for Managing Patients With Atrial Fibrillation. 25:S159-S160. 2022
EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. 25:S220-S220. 2022
EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. 25:S228-S228. 2022
EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. 25:S196-S196. 2022
EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. 25:S200-S200. 2022
EE214 Impact of Depression Relapse on Participant Quality of Life and Costs to the English NHS: Secondary Analysis from the Antler Study on Antidepressant Discontinuation in Well Patients in Primary Care. 25:S375-S375. 2022
EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors. 25:S428-S428. 2022
PCR105 The Impact of Key Health State Transitions on Health-Related Quality of Life (HRQOL) in Duchenne Muscular Dystrophy (DMD): A Qualitative Study. 25:S560-S561. 2022
PCR176 Time Trade-Off Utility Values for Health States Characterizing Progressive Muscular Degeneration in Duchenne Muscular Dystrophy (DMD). 25:S574-S574. 2022
The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment. 25:1253-1256. 2022
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. 25:869-886. 2022
Rasch Analysis of the Michigan Hand Questionnaire. 25:638-646. 2022
Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness. 25:178-184. 2022
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. 25:302-317. 2022
POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study. 25:S93-S93. 2022
POSC427 Platform Trials: A Path to Efficient Decision Making and Faster Drug Approvals for Health Technology Assessment Bodies. 25:S276-S276. 2022
SC3 The Drivers of Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Study Using the Health Utilities Index Mark 3 (HUI3). 24:S240-S240. 2021
Economic Consequences of Adult Living Kidney Donation: A Systematic Review. 24:592-601. 2021
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures. 24:556-567. 2021
Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate. 24:404-412. 2021
Acceptability and Validity of the EQ-5D in Patients Living With Dementia. 23:760-767. 2020
PNS18 IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT). 23:S286-S287. 2020
Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada. 23:74-88. 2020
PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS. 22:S521-S521. 2019
PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D). 22:S572-S572. 2019
PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS. 22:S810-S810. 2019
PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW. 22:S853-S853. 2019
Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy. 22:822-828. 2019
PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. 22:S248-S248. 2019
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. 21:318-325. 2018
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. 20:644-650. 2017
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. 20:644-650. 2017
The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic Evaluation. 20:556-566. 2017
A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly. 20:404-411. 2017
Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. 19:704-719. 2016
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. 19:300-315. 2016
A Discrete Choice Experiment (Dce) To Elicit Preferences For Attributes Of A Bedside Pharmacogenetic Test – Preliminary Results. 18:A399-A399. 2015
Heterogeneity in the Definition of Drug Induced Hypoglycemia in Clinical Trials: A Review. 18:A601-A601. 2015
Non-Comparative Trials To Supplement Network Meta-Analyses Using Arm-Specific Meta-Regression: An Application To Combination Therapies In Hiv. 18:A683-A684. 2015
Psychiatric Healthcare Utilization and Related Costs In Newly Diagnosed Individuals With Autism Spectrum Disorder (Asd) In Quebec (Canada). 18:A746-A747. 2015
The Use of Single-Arm Evidence In The Comparative Efficacy of Interferon-Free Antivirals for Treatment-Naïve Hepatitis C Genotype 1. 18:A576-A576. 2015
Use of Economic Evaluations of Health Technologies In Dutch Healthcare Decision-Making: Barriers And Facilitators. 18:A540-A540. 2015
Zrx Mcdm: A Fully Flexible Tool to Support The Local Adaptation of Multiple-Criteria Decision Criteria In Health Care. 18:A703-A703. 2015
An Assessment of the Association Between Rural Status and Health Service Resource Use Among Patients With Ankle Sprains in Ontario. 17:A388-A388. 2014
Comparative Efficacy and Safety of Empagliflozin with Other Anti-Diabetic Drugs for the Treatment of Patients with Type 2 Diabetes Mellitus Who are Failing Insulin. 17:A332-A333. 2014
Comparative Efficacy and Safety of Empagliflozin with Other Antidiabetic Drugs for the Third Line Treatment of Type 2 Diabetes Mellitus. 17:A333-A333. 2014
Comparative Efficacy and Safety of Empagliflozin with Other Oral Antidiabetic Drugs for the Second Line Treatment of Type 2 Diabetes Mellitus. 17:A333-A333. 2014
Comparative Efficacy of Umeclidinium Bromide Versus Other Long-Acting Anticholinergic Monotherapies as Treatments for Copd Patients. 17:A588-A589. 2014
Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients. 17:A595-A595. 2014
Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK. 17:A595-A595. 2014
Economic Evaluation of Bevacizumab Versus Ranibizumab in Neovascular Age-Related Macular Degeneration in China. 17:A782-A782. 2014
Impact of Demographics on Health Preferences in China: An Exploratory Analysis of China EQ-5D-5L Valuation Study. 17:A753-A753. 2014
Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies. 17:A740-A741. 2014
The Costs of Diagnosis and Treatment of Ankle Sprains and Fractures, 1980-2013: A Systematic Review. 17:A377-A377. 2014
Validating A Model To Predict Disease Progression Outcomes In Patients With COPD. 17:A560-A561. 2014
Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights. 17:77-83. 2014
Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment. 16:588-598. 2013
Measuring the Quality of a Childhood Cancer Care Delivery System: Assessing Stakeholder Agreement. 16:639-646. 2013
Measuring the Quality of a Childhood Cancer Care Delivery System: Quality Indicator Development. 16:647-654. 2013
Health utilities index®: Extending the age range to pre-schoolers. 16:A35-A36. 2013
Core Domains for a Person-Focused Outcome Measurement System in Cancer (PROMS-Cancer Core) for Routine Care: A Scoping Review and Canadian Delphi Consensus. 16:76-87. 2013
Economic Appraisal of a Community-Wide Cardiovascular Health Awareness Program. 16:39-45. 2013
PDB14 Characteristics of the Aboriginal People with Diabetes in the South-Western of Ontario, Canada. 15:A495-A496. 2012
Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada. 15:894-906. 2012
Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. 15:580-585. 2012
An Exploratory Study of Response Shift in Health-Related Quality of Life and Utility Assessment Among Patients with Osteoarthritis Undergoing Total Knee Replacement Surgery in a Tertiary Hospital in Singapore. 15:S72-S78. 2012
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT) (vol 14, pg 450, 2011). 14:963-963. 2011
The Use of a Decision Board to Elicit Brazilian Patients' and Physicians' Preferences for Treatment: The Case of Lupus Nephritis. 14:S141-S146. 2011
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT). 14:450-457. 2011
Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor. 14:240-246. 2011
Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation. 14:263-273. 2011
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?. 14:160-165. 2011
Erratum. 13:1065-1065. 2010
Functional Impairment and Disability across Mood States in Bipolar Disorder. 13:984-988. 2010
Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index. 13:873-878. 2010
Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. 13:487-494. 2010
Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. 13:S8-S11. 2010
Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis. 13:S15-S17. 2010
Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome. 13:411-417. 2010
PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. 13:A133-A133. 2010
PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. 13:A133-A134. 2010
Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature. 13:328-334. 2010
Effects of Mode and Order of Administration on Generic Health-Related Quality of Life Scores. 12:1035-1039. 2009
The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data. 12:847-856. 2009
Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting: A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data. 12:649-656. 2009
Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder. 12:624-627. 2009
A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. 12:245-252. 2009
Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease. 12:340-345. 2009
QALYs: The Basics. 12:S5-S9. 2009
Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making: an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. 11:365-375. 2008
Time and Expected Value of Sample Information Wait for No Patient. 11:522-526. 2008
Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip. 11:470-477. 2008
A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore. 11:S84-S90. 2008
Applying the Expectancy-Value Model to Understand Health Values. 11:S61-S68. 2008
The Association of Body Mass Index with Health-Related Quality of Life: An Exploratory Study in a Multiethnic Asian Population. 11:S105-S114. 2008
Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies: A Study in a Multiethnic Asian Population in Singapore. 11:S3-S10. 2008
Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. 10:415-430. 2007
Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based Instruments. 10:256-265. 2007
PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE. 8:A24-A25. 2005
MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN®TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE. 8:241-241. 2005
PMDI9: COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES: DOES IT MATTER?. 6:298-298. 2003
Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada. 6:116-125. 2003
PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION. 5:588-588. 2002
Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. 5:312-328. 2002
PHP50 HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND's DISEASE: MEASUREMENT PROPERTIES OF THE HEALTH UTILITIES INDEX. 5:158-158. 2002
POD7: THE EF-VAS: A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT. 4:468-469. 2001
PQP7: IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE?. 4:179-179. 2001
A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs. 4:16-31. 2001
TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER. 2:152-152. 1999
WMM2: ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH. 2:229-229. 1999
PCV10: A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM. 2:27-27. 1999
MGA5 Health Utilities Index: Further Evidence of Responsiveness. 1:41-41. 1998
MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada. 1:41-42. 1998
UT2 Practical Applications of the Health Utilities Index. 1:93-93. 1998

Value in Health Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)